Baik Brian Seung Won(백승원)

Baik Brian Seung Won(백승원) (chief executive) discloses dealings in 케이엠제약 to DART (FSS). Over a trading history stretching from 2 January 2024 to 30 July 2026, the count stands at 11 filings.

Both buying and selling appear: 10 purchases worth €300k, against 1 sale. The totals exclude 6 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show 8 purchases and 1 sale.

Half of the purchases are above €7,111 and half below. Measured against the company's value, the median purchase equals 0.087% of market capitalisation, across 4 purchases where it is known. 3 out of 8 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 50% of cases, with a median move of -21.2%. Past outcomes like these are no guarantee of what comes next.

The record was last updated on 30 July 2026 with an open-market purchase in 케이엠제약. The median gap between a trade and its publication by DART (FSS) is 7 days. Until a filing is published, the market cannot know about the trade. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.